抗凝剂协同平阳霉素治疗肿瘤的实验研究

EFFECT ON CHEMOTHERAPY IN CANCER INFLUENCE BY ANTICOAGULANTS

肿瘤的抗凝治疗是近十几年采新开展起来的一个研究领域。主要是用改善血液流变和微循环状态来协同增强化疗效果。本实验在地鼠颊囊癌模型建立后,在用平阳霉素化疗的同时加用抗凝剂华法令协同治疗,结果加用华法令组的地鼠平均生存时间比单用化疗组和空白组延长,三组地鼠平均存活天数分别是51.9,37.9和27.3天(P<0.01)。华法令加化疗组地鼠肿瘤的生长速度也明显比另两组慢(P<0.01)。华法令的抗肿瘤作用被认为是多途径的。但主要是以抗凝从而协同化疗为主。华法令阻止凝血因子发挥功能而降低血粘度,防止血液瘀滞,确保各器官血供和免疫功能的发挥。由于肿瘤区血流的增加而使大量免疫因子和抗癌药运到瘤体内发挥作用,使肿瘤细胞更易暴露在免疫因子而前而受攻击和消灭,还可以减少癌栓形成和防止瘤细胞着床。此外华法令可能还有一些其它方面的抗肿瘤作用,尚有待进一步研究。

Warfarin combination with pingyanmycinum treated golden hamster cheek pouch cancer which were induced by DMBA. Warfarin could do synergy and poteniation the chemothelapy action of pingyangmycinum. The existence period of animals was prolonged when hamster had been used warfarin by gastrogavage every day. The surival plase of treated group was 51.9 days and 37.9 days for the control group while the untreated gaoup's was 27.3 days (p<0.01). Warfarin combination with pingyangmycinum also could make degrowth of tumor, the growth rate of treated group was 44% and the control group's was 127% while the rate of the untreated group was 258% (P<0.01). Main reason about warfarin as synergist to chemotherapy was considered that it could be decreasing blood viscosity, of course there would be some other reasons which mechanisms were unclear.